Joscha Brinkmann

Joscha Brinkmann

Auto-generated profile, based on publicly available information

Joscha Brinkmann

Laboratory of Thermodynamics, TU Dortmund University, Emil-Figge-Str. 70, D-44227 Dortmund, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JBJoscha Brinkmann
Joscha Brinkmann
FHFabian Huxoll
Fabian Huxoll
CLChristian Lübbert
Christian Lübbert
GSGabriele Sadowski
Gabriele Sadowski

1 January 2018 in Fluid Phase Equilibria
Verified
Journal Article
Closed access
CHChristoph Held
Christoph Held
JBJoscha Brinkmann
Joscha Brinkmann
ASAnna-Dorina Schröder
Anna-Dorina Schröder
Mikhail I. YagofarovMikhail I. Yagofarov
Mikhail I. Yagofarov
Sergey P. VerevkinSergey P. Verevkin
Sergey P. Verevkin

5 May 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JBJoscha Brinkmann
Joscha Brinkmann
FRFrauke Rest
Frauke Rest
CLChristian Lübbert
Christian Lübbert
GSGabriele Sadowski
Gabriele Sadowski

12 March 2019 in Journal of Chemical & Engineering Data
Verified
Journal Article
Closed access
JBJoscha Brinkmann
Joscha Brinkmann
CLChristian Lübbert
Christian Lübbert
DZDzmitry Zaitsau
Dzmitry Zaitsau
Sergey P. VerevkinSergey P. Verevkin
Sergey P. Verevkin
GSGabriele Sadowski
Gabriele Sadowski

23 November 2020 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
JBJoscha Brinkmann
Joscha Brinkmann
LELara Exner
Lara Exner
CLChristian Lübbert
Christian Lübbert
GSGabriele Sadowski
Gabriele Sadowski
Purpose: This work proposes an in-silico screening method for identifying promising formulation candidates in complex lipid-based drug delivery systems (LBDDS). Method: The approach is based on a minimum amount of experimental data for API solubilites in single excipients. Intermolecular interactions between APIs and excipients as well as between different excipients were accounted for by the Perturbed-Chain Statistical Associating Fluid Theory. The approach was applied to the in-silico screening of lipid-based formulations for ten model APIs (fenofibrate, ibuprofen, praziquantel, carbamazepine, cinnarizine, felodipine, naproxen, indomethacin, griseofulvin and glibenclamide) in mixtures of up to three out of nine excipients (tricaprylin, Capmul MCM, caprylic acid, Capryol™ 90, Lauroglycol™ FCC, Kolliphor TPGS, polyethylene glycol, carbitol and ethanol). Results: For eight out of the ten investigated model APIs, the solubilities in the final formulations could be enhanced by up to 100 times compared to the solubility in pure tricaprylin. Fenofibrate, ibuprofen, praziquantel, carbamazepine are recommended as type I formulations, whereas cinnarizine and felodipine showed a distinctive solubility gain in type II formulations. Increased solubility was found for naproxen and indomethacin in type IIIb and type IV formulations. The solubility of griseofulvin and glibenclamide could be slightly enhanced in type IIIb formulations. The experimental validation agreed very well with the screening results. Conclusion: The API solubility individually depends on the choice of excipients. The proposed in-silico-screening approach allows formulators to quickly determine most-appropriate types of lipid-based formulations for a given API with low experimental effort. Graphical abstract

15 February 2021 in Journal of Chemical & Engineering Data
Verified
Journal Article
Closed access
JBJoscha Brinkmann
Joscha Brinkmann
LELara Exner
Lara Exner
Sergey P. VerevkinSergey P. Verevkin
Sergey P. Verevkin
CLChristian Lübbert
Christian Lübbert
GSGabriele Sadowski
Gabriele Sadowski